Hong Kong Earnings Season: Why Some Stocks Rise While Others Fall Despite Profit Growth

Six companies' earnings reports show a comparison between growth rates and post-earnings stock price reactions; growth metrics vary, and the reaction windows are explained in the chart.

From October 20 to 23, the Hang Seng Index declined by 4.52% cumulatively, while the Hang Seng Tech Index fell by 5.76%. On October 22 alone, the Hang Seng Index dropped 3.03%, and the Hang Seng Tech Index declined 5.03%. During the same period, net outflows from southbound funds amounted to approximately HK$17.046 billion, with net selling occurring on all four trading days. The greater pullback in technology stocks indicates that this pressure has not been evenly distributed across all assets—high-volatility growth stocks have experienced amplified fluctuations in response to shifts in risk appetite.

The Hang Seng Tech Index closed lower, declining 5.76% cumulatively from October 20 to 23, during which time net outflows from southern capital amounted to approximately HK$17.046 billion.

At least three forces are at play. First, the global correction in technology stocks has reignited discussions about the return cycle of AI capital expenditures. In the past, markets were willing to assign higher valuations to computing power, semiconductors, and AI infrastructure, as investors believed today’s investments would translate into future revenue and profits. As spending continues to grow and commercial returns still require time to materialize, valuations must be recalibrated. Demand for AI has not disappeared—what has changed is the timing of revenue realization, along with the weighting of profit margins and capital returns in pricing.

Second is the gap between policy expectations and actual data. When the market has already priced in the possibility of intensified stimulus policies, even if economic data does not worsen, it may not be sufficient to drive valuations higher. Stock prices reflect changes in actual outcomes relative to prior market expectations; isolated economic data alone does not provide a complete answer. Third, southbound funds have turned net outflows, increasing adjustment pressure on sectors that have seen significant prior gains and concentrated holdings.

However, index pressure does not equate to uniform bearishness on growth. What truly matters is which companies can still demonstrate growth sufficient to convince investors when overall valuations are under pressure. Index pressure stems from valuations, policy expectations, and capital flows; the real insight from earnings season lies in stock-level divergence. HSBC and CATL reveal discounts behind impressive numbers, while Hengrui Medicine, WuXi AppTec, and ASMPT showcase different types of growth evidence. China Shenhua further illustrates that the market is willing to buy not just high-growth stocks, but also those offering more certain cash returns.

HSBC's third-quarter financial results appeared solid. The company reported pre-tax profits of $9.632 billion, a 32% year-over-year increase. Post-tax profits rose 38% to $7.6 billion, while net interest income reached $9.3 billion, up 6% year-over-year. The company also announced a third interim dividend of $0.10 per share and plans to initiate a share buyback program of up to $1 billion. However, following the earnings announcement, HSBC's stock closed down 5.56% at HK$134.30 on the Hong Kong trading day.

After excluding the $1.421 billion legal reserve base, HSBC's profit growth rate reverted to approximately 10%.

To understand this contrast, first break down the 32% profit increase. In the same period of 2025, HSBC set aside approximately $14.21 billion in legal provisions related to a claim in Luxembourg concerning the Madoff fraud; there were no similar expenses this period, resulting in a significant year-over-year base effect. Excluding exceptional items and adjusting for constant exchange rates, HSBC’s pre-tax profit for the third quarter was approximately $10.021 billion, representing a year-over-year increase of about 10%—a notable gap from the reported 32%. Meanwhile, the company’s revenue stood at $18.62 billion, up 4.7% year-over-year but below the market expectation of $18.93 billion. Wealth management revenue was approximately $2.7 billion, roughly flat year-over-year, with growth failing to sustain the strong momentum seen in the previous two quarters.

This does not mean HSBC’s operations have suddenly deteriorated. The net interest margin remains at 1.57%, the annualized tangible return on equity is 17.7%, and dividends and share buybacks continue to support shareholder returns. The issue is that when investors review earnings reports, they don’t just look at whether profits have grown—they assess the composition of that growth: how much stems from operational improvements, how much comes from a low base last year, and how much is sustainable in future quarters.

HSBC's stock price reaction clearly illustrates this distinction. One-time provisions no longer occur, which can boost current profits but won't generate the same level of earnings annually. When revenue growth falls short of expectations, the market may revise down its forecasts for future profitability. Profit growth is a realized outcome; it is sustained profitability that investors are truly valuing. The market had expected the company to raise its guidance further—no matter how impressive the reported growth figures, they may still fail to support the stock price.

If HSBC's issue lies in the proportion of one-time factors in its profit growth, CATL faces a different, more noteworthy divergence: revenue, profit, and cash flow are not growing in sync.

In the third quarter, CATL's revenue reached RMB 165.221 billion, representing a 58.58% year-over-year increase and an 11.8% sequential growth. Net profit attributable to shareholders was RMB 21.246 billion, up 14.54% year-over-year but down 5.77% sequentially from the second quarter, falling below expectations from institutions such as Bernstein and Goldman Sachs. For the first nine months of the year, the company's revenue totaled RMB 442.137 billion, up 56.19% year-over-year, with net profit attributable to shareholders at RMB 64.530 billion, up 31.60% year-over-year. While the trend of rapid revenue growth remains intact, the profit growth in the third quarter significantly lagged behind revenue growth.

Cash flow data highlights this disparity. For the first nine months, CATL’s net cash flow from operating activities amounted to RMB 61.625 billion, a 23.60% year-over-year decline. Breaking it down by the interim and third-quarter reports, the net cash flow from operating activities for the third quarter alone was approximately RMB 1.409 billion, a 93.59% year-over-year drop—the lowest quarterly level since Q2 2018—and significantly below the net profit for the same period. Company management attributed the cash flow changes to adjustments in supplier payment terms and advance payments, while the period’s profitability was impacted by shifts in product mix and tax policy changes. The company expects continued market demand growth through 2027. Subsequently, the company announced an A-share repurchase plan of approximately RMB 800 million, but repurchases cannot substitute for careful analysis of operating data.

Comparison of CATL's revenue, profit, and operating cash flow growth rates; the right chart shows the H-share closing price trend.

The stock performance reflects the market's caution regarding these differences. On October 20, CATL's H-shares closed down 6.58%. On October 21, they fell another 11.41%, and on October 22, they declined by 7.24%. As of 3:45 PM on October 28, the stock price stood at HK$346.80, down approximately 0.5% from the previous trading day's closing price.

It cannot be simply concluded that “cash flow decline means deteriorating growth quality.” Operating cash flow is influenced by payment cycles, advance payments, and changes in working capital, and single-quarter data may exhibit significant fluctuations. The three key questions that truly need to be answered are: Is revenue growth driven by volume expansion or changes in product and pricing mix? Is the slower profit growth relative to revenue due to a temporary product mix or competitive and cost pressures? Is the decline in cash flow a temporary disruption caused by settlement timing, or does it reflect a more persistent reduction in the ability to convert profits into cash?

These three lines determine how to interpret the upcoming financial report. If revenue continues to grow, profit margins gradually stabilize, and operating cash flow subsequently recovers, this quarter’s divergence may stem from temporary factors. If revenue continues to expand but profits and cash flow remain lagging over the long term, the economic value of this growth must be reassessed. For CATL, the most critical task in the next phase is to demonstrate that demand growth can be translated into profits and ultimately into cash flow.

Compared to HSBC and CATL, Hengrui Pharma’s financial report received a more positive market response. The company disclosed on the evening of October 27 that its third-quarter revenue reached RMB 8.953 billion, a 20.55% year-over-year increase; attributable net profit amounted to RMB 2.458 billion, up 88.92% year-over-year; and non-GAAP attributable net profit reached RMB 2.514 billion, up 90.93% year-over-year. The net cash flow from operating activities in the third quarter was RMB 5.857 billion, up 21.76% year-over-year. On October 28, Hengrui’s H-shares surged more than 12% intraday and were trading up approximately 10.9% by 3:45 PM, at HK$49.58.

In the third quarter, Hengrui Pharmaceutical's four core metrics showed growth. The right chart shows that innovative drug sales accounted for 64.59% of total drug sales in the first nine months; the amounts for other drugs were calculated by reversing the proportions disclosed in the announcement.

However, to understand this surge in growth, you cannot focus solely on the 88.92% net profit increase. According to Hengrui’s announcement, the rise in revenue from external licensing was one of the key factors behind the strong quarterly profit growth. For innovative pharmaceutical companies, revenue is not limited to drug sales—upfront and milestone payments from overseas licensing partnerships also contribute significantly to income and profits. These collaborations reflect the R&D value and potential commercialization scope of a product, but revenue recognition is uneven over time; a single quarter’s profit growth rate cannot be directly extrapolated to predict future quarterly performance.

On the other hand, Hengrui is not entirely reliant on one-time licensing income. In the first nine months, the company's sales revenue from innovative drugs reached RMB 13.871 billion, a year-over-year increase of 17.05%, accounting for 64.59% of total drug sales revenue, with cumulative R&D investment of RMB 7.146 billion. The growth rate of adjusted net profit in the third quarter was close to that of net profit attributable to shareholders, indicating that the improvement in profitability was not solely driven by non-recurring gains.

Therefore, what truly matters in Hengrui’s financial report is whether the three pathways—sales of innovative drugs, R&D achievements, and out-licensing—can form a mutually supportive profit structure. Drug sales provide sustained operating revenue, R&D investment determines future product pipelines, and overseas licensing can accelerate the commercialization of innovation. Simultaneous improvement across all three areas holds greater long-term significance than a sudden spike in quarterly profit growth.

Authorized revenue has another side: it can significantly boost current-period profits but may cause quarterly fluctuations due to the timing of transactions and recognition. If profit growth slows in subsequent periods, it cannot be immediately assumed that operations are deteriorating, nor should the current high growth be simplistically viewed as the new norm. Further analysis is needed to distinguish between changes in the base of authorized revenue, sustained growth in novel drug sales, and whether research outcomes can continue to translate into new partnerships and commercial returns.

Hengrui's price increase shows that the market is willing to pay for growth in innovative pharmaceutical companies, provided investors understand the source of that growth and believe it can be sustained. What truly determines valuation is whether different revenue streams can together form a sustainable profit model.

Hengrui demonstrated that revenue and profits can be driven by multiple sources, while WuXi AppTec and ASMPT offer another perspective: compared to quarterly profits, orders and guidance help investors assess whether future business operations are still expanding. However, orders have their own limitations: receiving orders does not equate to delivery, delivery does not guarantee high profitability, and record-breaking orders do not necessarily mean future revenue will grow at the same rate.

WuXi AppTec reported revenue of RMB 45.537 billion for the first nine months of the year, a 38.59% year-over-year increase. Net profit attributable to shareholders was RMB 19.398 billion, up 60.64% year-over-year, while non-GAAP net profit increased by 73.03%. For the third quarter, net profit attributable to shareholders was RMB 8.318 billion, a 136.67% year-over-year increase, including a one-time gain of approximately RMB 3.102 billion from the sale of a portion of its equity interest in associate WuXi XDC. The non-GAAP quarterly net profit growth rate of 49.85% better reflects the performance of its core business.

More worth tracking than quarterly profit is the company’s $76.74 billion in outstanding orders as of the end of September, a 36.4% year-over-year increase, with a net addition of approximately $10.3 billion for the quarter. The company also raised its full-year revenue guidance from $58.5 billion to $60.5 billion to $61.0 billion to $61.9 billion, and increased its adjusted free cash flow forecast to $14.5 billion to $15.5 billion. The growth in orders, upward revision of revenue guidance, and improved cash flow expectations form a consistent set of signals, indicating that business demand is not only reflected in recognized revenue but also in the volume of work yet to be delivered.

WuXi AppTec's backlog increased by approximately RMB 17 billion net in the second and third quarters, while ASMPT recorded a record-high single-quarter order intake, calculated backward based on the growth rate stated in the announcement.

ASMPT's order data stands out more prominently. The company reported its third-quarter results on October 28, with revenue of HK$5.247 billion, a 48.7% year-over-year increase. Total new orders reached HK$8.845 billion, a 137.9% year-over-year increase and a record high, up 24.7% quarter-over-quarter. The order-to-ship ratio reached 1.69, the highest level since the first quarter of 2021. The company expects fourth-quarter revenue to range between $670 million and $730 million, representing approximately a 4.6% quarter-over-quarter increase and a 37.5% year-over-year increase based on the midpoint of the guidance range.

These data provide more direct evidence of demand in the AI supply chain than conceptual narratives. For AI investments to translate into revenue for supply chain companies, it ultimately requires customer orders, equipment delivery, and revenue recognition. ASMPT’s new orders and guidance for the fourth quarter at least offer a trackable basis for business performance over the next several quarters. However, the company also noted that the order growth includes one-time large orders and customers placing orders earlier due to extended delivery cycles. In other words, the order growth is a genuine operational signal, but should not be mechanically interpreted as a 137.9% year-over-year increase in future revenue.

Market reactions have not been consistently upward. After reporting earnings on October 27, Wuxi AppTec opened more than 4% higher; by 15:45 on October 28, it had risen approximately 2.2%. ASMPT opened nearly 5% higher on its earnings announcement day, but later declined in the afternoon, closing at HK$117.30 at 15:45—about 3.2% lower than the previous day’s closing price. This reminds investors that even with improved operational metrics, stock prices depend on whether these improvements exceed prior expectations, whether valuations have already priced in these gains, and how investors assess the pace at which future orders will be fulfilled.

The commonality between WuXi AppTec and ASMPT is that they both provide measurable operational metrics—order volume, revenue guidance, and cash flow expectations. Their difference lies in the fact that WuXi AppTec’s backlog more directly reflects future pipeline volume, while ASMPT’s new orders require further observation of delivery cycles, customer ordering patterns, and product mix. In the next phase, whether orders translate into revenue, revenue into profits, and profits into cash flow will be the key to assessing the quality of growth.

If Hengrui, WuXi AppTec, and ASMPT represent different forms of growth, China Shenhua offers another pricing logic: growth doesn’t need to be rapid; as long as current earnings and shareholder returns are sufficiently clear, it can still be attractive.

In the third quarter, China Shenhua's attributable net profit reached RMB 15.688 billion, a 3.2% year-over-year increase, with non-GAAP net profit rising 10.6% year over year. For the first nine months of the year, the company's revenue amounted to RMB 296.031 billion, up 9.0% year over year; attributable net profit totaled RMB 44.403 billion, up 3.8% year over year; and net cash flow from operating activities reached RMB 92.7 billion, up 23.1% year over year. Based on the 2025 dividend payout ratio, the company's dividend yield as of October 26 was approximately 4.52%.

China Shenhua's cash flow growth in the first nine months significantly outpaced its profit growth. The right chart shows year-over-year coal price changes and dividend yield levels.

Compared to innovative pharmaceutical companies and AI supply chain firms, China Shenhua does not need to rely on rapid growth to justify its full investment value. For such assets, investors are more concerned with changes in coal and electricity prices, the stability of long-term contract mechanisms, capital expenditures, and whether operating cash flow can cover dividends. The spot price of 5,500 kcal coal in Qinhuangdao rose 31.3% year-over-year, while the long-term contract price increased by 5.0%, providing support for cash flow. A relatively modest profit growth rate does not necessarily imply reduced investment appeal. When cash flow is stable, capital allocation discipline is clear, and dividends are sustainable, investors may still be willing to pay a price for current returns.

High dividends also require verification. Declining commodity prices, rising capital expenditures, or sustained profit declines could weaken future dividend capacity. The dividend yield is a return metric calculated based on the current stock price and does not guarantee future dividends. What truly matters is how much sustainable free cash flow supports the dividend and whether the company must sacrifice essential investments to maintain payouts.

The difference between China Shenhua, Hengrui, and WuXi AppTec lies in the distinct questions they must answer. Growth companies must demonstrate that future profits will be realized, while cash return companies must prove that current earnings are sustainable. The market is now re-evaluating the certainty of growth, risk, and cash returns across different assets—a simple growth-versus-value dichotomy fails to capture this shift.

Putting these cases together makes the logic behind the earnings divergence clearer. The market is not uniformly rewarding high profit growth, high orders, or high dividends. Instead, it is looking for which metric best demonstrates that a company’s growth or returns can continue in line with market expectations.



The value of this framework lies in helping investors understand what to look at next; it cannot directly predict individual stock performance based on a single number. A high profit growth rate doesn’t guarantee future profits will be even higher. Rapid order growth doesn’t mean all orders will be delivered on time. Strong cash flow doesn’t ensure stable dividends forever. Each metric answers a different question—only when viewed within the context of the company’s business model, balance sheet, and valuation expectations can a complete assessment be formed.

It’s also important to emphasize that stock prices reflect changes relative to expectations, which is far more complex than simply grading financial reports. Even if a company’s performance improves, the stock price may still decline if it falls short of market expectations. Conversely, even if growth is modest, the stock price may rise if actual performance exceeds pessimistic forecasts. The so-called verifiability premium does not mean the market is willing to pay only for cash flows or orders; rather, it means that when valuations are under pressure and capital becomes more cautious, investors place greater emphasis on the source of growth, the path to realization, and its sustainability.

The current correction in the Hong Kong stock market primarily reflects pressures on overall valuations and the funding environment. The divergence in individual stock performance is more closely tied to the relationship between earnings expectations, growth quality, and valuation. Temporary net outflows of southbound funds can indicate the prevailing funding conditions at the time, but they are insufficient to prove a long-term structural shift from growth to value. Confirming such a shift requires continued monitoring of subsequent capital flows, relative sector performance, and whether stock prices sustain their reactions following company earnings reports.

HSBC, CATL, Hengrui Medicine, WuXi AppTec, ASMPT, and China Shenhua represent six distinct operational and pricing scenarios. HSBC must demonstrate that its core profit improvement is not merely due to base effects; CATL needs to realign revenue, profits, and cash flow into a more reasonable balance; Hengrui must prove that licensing income and sales of innovative drugs can jointly support profitability; WuXi AppTec and ASMPT need to convert orders into revenue and cash flow; and China Shenhua must demonstrate the sustainability of its current cash returns.

None of these companies can be definitively assessed based on a single quarter's numbers. However, collectively, they point to a noteworthy trend worth monitoring: in a market under valuation pressure, growth remains important, but investors are increasingly demanding clarity on how that growth is being realized.

Next, whether CATL can restore its operating cash flow, whether WuXi AppTec’s orders can continue to convert, whether ASMPT’s high order backlog can be realized as future revenue, and whether Hengrui’s innovative drug business can sustain growth, will provide new evidence for this assessment. If subsequent financial reports show that profit growth driven by one-time factors continues to receive the same valuation response as improvements in core operations, then the explanation for the verifiability premium will need to be revised. What the market ultimately rewards is not determined by any single concept, but will be answered by the next earnings report.

• HSBC Holdings Q3 Earnings and Stock Market Reaction: Company Earnings Announcement, 21st Century Business Herald, China News Service, October 27–28, 2026
• Sinopec, WuXi AppTec, China Shenhua Q3 reports: Company announcements, Xinhua Finance, Shanghai Securities News, October 23–27, 2026
• CATL Q3 Report, Earnings Call, and Quarterly Cash Flow Breakdown: Company Announcements, Caijing.com, Phoenix Finance, Sohu Finance, October 20–23, 2026
• ASMPT Q3 Performance: Company Earnings Announcement, Caixin Finance, Zhitong Financial, October 28, 2026
• Coal price and dividend yield calculation: Reports from institutions such as Everbright Securities (cited), October 26–27, 2026
• Hang Seng Index, Hang Seng Tech Index, and Southbound Funds: Public Market Statistics, October 20–23, 2026, Hang Seng Tech closing levels verified with market data.

Disclaimer: The content of this article is provided solely for general information and market commentary, based on publicly available data as of the time mentioned herein. Market data and expectations referenced herein may change due to market conditions. Opinions and investment strategies cited from third-party institutions, analysts, or other individuals reflect only their views at a specific point in time and do not represent BIT’s views or recommendations. This article does not constitute investment advice, research, an offer, solicitation, or recommendation for any securities, investment products, or trading strategies, and should not be used as the basis for any investment decision. Financial markets involve risks; security prices and market performance may fluctuate, and historical performance or past market trends do not indicate or guarantee future results. Investors should independently assess relevant risks based on their own circumstances and seek professional advice when necessary. BIT’s Hong Kong stock trading services are not available to residents of Hong Kong or users in other restricted jurisdictions.